Molindone hydrochloride: A review of laboratory and clinical findings

Journal of Clinical Psychopharmacology

Volumn 9, Issue 4, 1989, Pages 268-276

  Owen, Richard R ^a   Cole, Jonathan O ^b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE RECEPTOR; MOLINDONE;

ANXIETY; BODY WEIGHT; DRUG THERAPY; HUMAN; PSYCHOLOGICAL ASPECT; SCHIZOPHRENIA; SHORT SURVEY; TARDIVE DYSKINESIA; THEORETICAL STUDY;

ADULT; ANIMAL; BEHAVIOR, ANIMAL; CHILD; CORPUS STRIATUM; HUMAN; INDOLES; MOLINDONE; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

EID: 0024370077     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Rubin AA, Yen HC, Pfeffer M. Psychopharmacological profile of molindone. Nature 1967;216:578–9.
2. Gilder DA, Fain W, Simpson LL. A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine. J Pharmacol Exp Ther 1976;198:255–63.
3. Balsara JJ, Nandal NV, Gada VP, et al. Effect of drugs influencing central 5–hydroxytryptaminergic mechanisms on molindone-induced catalepsy in the rat. J Pharm Pharmacol 1981;33:392–4.
4. Barrett JE. Comparison of the effects of antipsychotic drugs on the schedule-controlled behavior of squirrel monkeys and pigeons. Neuropharmacology 1983;22:519–24.
5. Guerrero-Figueroa R, Guerrero-Figueroa E, Sneed GA, et al. Effects of molindone on CNS structures: neurophysiological and behavioral correlations. Curr Ther Res 1973;15:508–19.
6. Oliver AP, Luchins DJ, Wyatt RJ. Neuroleptic-induced seizures. An in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982;39:206–9.
7. Nandal NV, Balsara JJ, Mane VR, et al. Effect of molindone pretreatment on apomorphine induced vasodepressor response, stereotypy and cage climbing behavior. Indian J Pharmacol 1980;12:157–64.
8. Beymer CH, Quock RM. Molindone: an apomorphine antagonistin the rabbit. Commun Psychopharmacol 1977;1:385–92.
9. Simpson LL. Combined use of molindone and guanethidine in patients with schizophrenia and hypertension. Am J Psychiatry 1979;136:1410–4.
10. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:92–6.
11. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717–9.
12. Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984;45:331–6.
13. Creese I, Stewart K, Snyder SH. Species variations in dopamine receptor binding. Eur J Pharmacol 1979;60:55–66.
14. Rosenfeld MR, Dvorkin B, Klein PN, et al. Differential affinities of molindone, metoclopramide and domperidone for classes of[3H] spiroperidol binding sites in rat striatum; evidence for pharmacologically distinct classes of receptors. Brain Res 1982;235:205–11.
15. Beart PM, McDonald D. Neurochemical studies of the mesolimbic dopaminergic pathway [3H] spiperone labels two binding sites in homogenates of the nucleus accumbens of rat brain. J Neurochem 1982;39:1452–60.
16. Gundlach AL, McDonald D, Beart PM. [3H] spiperone labels noncyclase-linked dopamine receptors in the ventral tegmental area of rat brain. J Neurochem 1982;39:890–4.
17. Thal LJ, Makman MH, Ahn HS, et al. 3H–spiroperidol binding and dopamine stimulated adenylate cyclase: evidence for multiple classes of receptors in primate brain regions. Life Sci 1978;23:629–33.
18. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984;103:197–204.
19. Meller E. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats. Psychopharmacology 1982;76:222–7.
20. Koller W, Curtin J, Fields J. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia. Neuropharmacology 1984;23:1191–4.
21. Hyttel J. Effects of neuroleptics on 3H–haloperidol and 3H–cis (z)flupenthixol binding and on adenylate cyclase activity in vitro. Life Sci 1978;23:551–5.
22. Koe BK. Biochemical assessment of the neuroleptic activity of molindone. In: Usdin E, Kopin IJ, Barchas J, eds. Catecholamines: basic and clinical frontiers. Proceedings of the Fourth International Catecholamine Symposium. New York: Pergamon Press, 1979:740–2.
23. Robinson SE, Berney S, Mishra R, et al. The relative role of dopamine and norepinephrine receptor blockade in the action of antipsychotic drugs: metoclopramide, thiethylperazine, and molindone as pharmacological tools. Psychopharmacology 1979;64:141–7.
24. Ahn HS, Makman MH. Serotonin sensitive adenylate cyclase activity in monkey anterior limbic cortex: antagonism by molindone and other antipsychotic drugs. Life Sci 1978;23:507–11.
25. Sachar EJ, Gruen PH, Altman N. The use of the prolactin response in clinical psychopharmacology. Psychopharmacol Bull 1977;13:60–1.
26. Rosenberg JM, Lau-Cam CA. Small animal model for evaluating neuroleptic potency. J Pharm Sci 1980;69:74–7.
27. Juorio AV. Effects of molindone and fluphenazine on the brain concentration of some phenolic and catecholic amines in the mouse and the rat. Br J Pharmacol 1980;70:475–80.
28. Meller E, Friedman E. Differential dose– and time–dependent effects of molindone on dopamine neurons of rat brain: mediation by irreversible inhibition of monoamine oxidase. J Pharmacol Exp Ther 1982;220:609–15.
29. Balsara JJ, Gada VP, Nandal NV, et al. Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic. J Pharm Pharmacol 1984;36:608–13.
30. Roth JA, Whittemore RM, Shakarjian MP, et al. Inhibition of human brain type A and B monoamine oxidase by chlorpromazineand metabolites. Commun Psychopharmacol 1979;3:235–43.
31. Arora RC, Meltzer HY. In vitro and in vivo inhibition of rat liver, brain and muscle monoamine oxidase by chlorpromazine and imipramine. Res Commun Chem Path Pharmacol 1976;14:755–8.
32. Giller E, Hall H, Reubens L, et al. Haloperidol inhibition of monoamine oxidase in vivo and in vitro. Biol Psychiatry 1984;19:517–23.
33. Leelavathi DE, Smith RC. Chronic neuroleptics and brain monoamine oxidase activity. Biol Psychiatry 1980;15:479–84.
34. DeLisi LE, Wise CD, Bridge TP, et al. A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Res 1981;4:95–107.
35. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217–9.
36. Walters JR, Roth RH. Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch Pharmacol 1976;296:5–14.
37. Alander T, Grabowska-Andén M, Andén NE. Physiological significance of dopamine autoreceptors as studied following their selective blockade by molindone. J Pharm Pharmacol 1980;32:780–2.
38. Conway P, Uretsky NJ. Enhanced stereotyped response to amphetamine after pretreatment with small doses of molindone. Neuropharmacology 1983;22:579–86.
39. Fuller RW, Snoddy HD. Molindone: higher doses needed to block pergolide-induced elevation of serum corticosterone than to elevate dopmaine metabolites in brain. Life Sci 1983;33:2357–61.
40. Bunney BS, Roth RH, Aghajanian GK. Effects of molindone on central dopaminergic neuronal activity and metabolism: similarity to other neuroleptics. Psychopharmacol Commun 1975;1:349–58.
41. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221:1054–7.
42. Zetin M, Cramer M, Garber D, et al. Bioavailability of oral and intramuscular molindone hydrochloride in schizophrenic patients. Clin Ther 1985;7:169–75.
43. Fann WE, Moreira AF. Neuroleptic bioequivalency: tablet versus concentrate. J Clin Pharmacol 1985;25:305–6.
44. Freedberg KA, Innis RB, Creese I, et al. Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sci 1979:24:2467–73.
45. Wolf ME, Mosnaim AD, Owen R, et al. Molindone pharmacokinetics in psychiatric patients. Res Commun Psychol Psychiatry Behav 1985;10:215–20.
46. Claghorn JL. Review of clinical and laboratory experiences with molindone hydrochloride. J Clin Psychiatry 1985;46(8, suppl):30–3.
47. Wolf ME, Mosnaim AD. Lithium and molindone interactions: pharmacokinetic studies. Res Commun Psychol Psychiatry Behav 1986;11:23–8.
48. Ayd FJ. A critical evaluation of molindone (Moban): a new indole derivative neuroleptic. Dis Nerv Sys 1974;35:447–52.
49. Greengard P. Presynaptic and postsynaptic roles of cyclic AMP and protein phosphorylation at catecholaminergic synapses. In: Almgren O, Carlsson A, Engel J, eds. Chemical tools in catecholamine research II. Amsterdam: North Holland Publishing, 1975:249–56.
50. Cohen BM, Lipinski JF. Radioreceptor assays and blood levels of neuroleptics. In: Usdin E, Bunney WE, Davis JM, eds. Neuroreceptors: basic and clinical aspects. New York: John Wiley and Sons, 1981;199–214.
51. Tune LE, Creese I, DePaulo JR, et al. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients. J Nerv Ment Dis 1981;169:60–3.
52. Sugerman AA, Herrmann J. Molindone: an indole derivative with antipsychotic activity. Clin Pharmacol Ther 1967;8:261–5.
53. Shelton J, Prusmack JJ, Hollister LE. Molindone, a new type of antipsychotic drug. J Clin Pharmacol 1968;8:190–5.
54. Simpson GM, Krakov L. A preliminary study of molindone (EN-1733A) in chronic schizophrenia. Curr Ther Res 1968;10:41–6.
55. Turek IS, Ota KY, De La Rocha M, et al. The use of molindone in the treatment of acute psychotic states: comparison of two dosage schedules. J Clin Pharmacol 1970;10:349–55.
56. Itil T, Heinemann LG, Keskiner A, et al. Digital computer analyzed resting and sleep EEG investigations and clinical changes during molindone treatment. J Psychiatr Res 1971;9:45–9.
57. Krumholz WV, Sheppard C, Merlis S. Menstruation changes as unusual side effect in a molindone trial. Curr Ther Res 1970;12:94–6.
58. Abuzzahab FS. Treatment of acute schizophrenia with molindone. J Clin Pharmacol 1973;13:226–33.
59. Abuzzahab FS. Long-term use of molindone in schizophrenics. J Clin Pharmacol 1973;13:422–6.
60. Gallant DM, Bishop MP, Steele CA, et al. Molindone: a crossover evaluation of capsule and tablet formulations in severely ill schizophrenic patients. Curr Ther Res 1973;15:915–8.
61. Kellner R, Rada RT, Egelman A, et al. Long-term study of molindone hydrochloride in chronic schizophrenics. Curr Ther Res 1976;20:686–94.
62. Gallant DM, Bishop MP. Molindone: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res 1968;10:441–7.
63. Claghorn JL. Psychopharmacologic charateristics of an indole compound-molindone. Curr Ther Res 1969;11:524–7.
64. Freeman H, Frederick AND. Comparison of trifluoperazine and molindone in chronic schizophrenic patients. Curr Ther Res 1969;11:670–6.
65. Ramsay RA, Lehmann HE, Ban TA, et al. Clinical evaluation of a new psychotropic drug-molindone. Int J Clin Pharmacol 1970;3:46–8.
66. Simpson GM, Amin M, Edwards JG. A double-blind comparison of molindone and trifluoperazine in the treatment of acute schizophrenia. J Clin Pharmacol 1971;11:227–36.
67. Itil TM, Polvan N, Ucok A, et al. Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients. Behav Neuropsychiatry 1971;3:25–32.
68. Brauzer B, Goldstein BJ. A clinical comparison of molindone hydrochloride with trifluoperazine in psychotic outpatients. Curr Ther Res 1971;13:152–7.
69. Clark ML, Huber WK, Sakata K, et al. Molindone in chronic schizophrenia. Clin Pharmacol Ther 1970;11:680–8.
70. Claghorn J. Differential drug effects on social and symptomatic behaviors. Curr Ther Res 1970;12:580–4.
71. Binder R, Glick I, Rice M. A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient. J Clin Psychiatry 1981;42:203–6.
72. Smythies JR, Hain J, Crews E, et al. A clinical trial of injectable molindone (Moban®). Curr Ther Res 1982;32:752–6.
73. Escobar JI, Mann JJ, Keller J, et al. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. J Clin Psychiatry 1985;46(8, suppl):15–9.
74. Gardos G, Cole JO. Weight reduction in schizophrenics by molindone. Am J Psychiatry 1977;134:302–4.
75. Parent MM, Roy S, Sramek J, et al. Effect of molindone on weight change in hospitalized schizophrenic patients. Drug Intell Clin Pharm 1986;20:873–5.
76. Gomez EA. Neuroleptic-induced priapism. Tex Med 1985;81:47–8.
77. Bhatia SC, Banta LE, Ehrlich DW. Molindone and hepatotoxicity. Drug Intell Clin Pharm 1985;19:744–6.
78. Johnson SB, Alvarez WA, Freinhar JP. A case of massive rhabdomyolysis following molindone administration. J Clin Psychiatry 1986;47:607–8.
79. Glickman L. Rhabdomyolysis and acute renal failure (letter). J Clin Psychiatry 1987;48:299.
80. Pandurangi AK, Narasimhachari N. Rhabdomyolysis and molindone (letter). J Clin Psychiatry 1988;49:37.
81. Case WG, Chung HR, Pereira-Ogan JA, et al. Molindone in anxious neurotic outpatients: a pilot study. Curr Ther Res 1970;12:136–41.
82. Kellner R, Gervais RH, Pathak D. A pilot study of the short-term antianxiety effects of molindone HC1. J Clin Pharmaco1 1972;12:472–6.
83. Rickels K, Hutchison J, Morris RJ, et al. Molindone and chlordiazepoxide in anxious neurotic outpatients. Curr Ther Res 1972;14:1–9.
84. Carranza-Acevedo J, Tovar-Acosta H. Clinical evaluation of the efficacy of molindone and chlordiazepoxide in anxious outpatients. Cur Ther Res 1972;14:609–14.
85. Shader RI, Harmatz JS. Molindone: a pilot evaluation during the premenstruum. Curr Ther Res 1975;17:403–6.
86. Mirabi M, Mathew RJ, Claghorn J.. When is a neuroleptic appropriate in psychoneurosis? Curr Ther Res 1978;23:101–4.
87. Mendels J, Krajewski TJ, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986;47:170–4.
88. Goldstein BJ, Brauzer B. Comparison of molindone and placebo in anxious depressed patients. Curr Ther Res 1971;13:344–9.
89. Small JG, Kellams JJ, Dennis JL, et al. Comparison of molindone and tranylcypromine in the treatment of refractory depression. J Clin Pharmacol 1981;21:351–8.
90. Robertson MM, Trimble MR. Major tranquilisers used as antidepressants. A review. J Affective Disord 1982;4:173–93.
91. Campbell M, Fish B, Shapiro T, et al. Study of molindone in disturbed preschool children. Curr Ther Res 1971;13:28–33.
92. Greenhill LL, Barmack JE, Spalten D, et al. Molindone hydrochloride in the treatment of aggressive, hospitalized children. Psychopharmacol Bull 1981;17:125–7.
93. Greenhill LL, Solomon M, Pleak R, et al. Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 1985;46(8, suppl):20–5.
94. Peper M. Clinical experience with molindone hydrochloride in geriatric patients. J Clin Psychiatry 1985;46(8, suppl):26–9.
95. Camp EW III. Tardive dyskinesia. Oral facial dyskinesia with Moban (letter). Dis Nerv Sys 1977;38:759.
96. Ananth J, Carrillo R. Tardive dyskinesia with molindone (letter). J Clin Psychiatry 1983;44:276.
97. Cole JO, Gardos G, Schniebolk S. Differences in incidence of tardive dyskinesia with different neuroleptics. In: Casey DE, Gardos G, eds. Tardive dyskinesia and neuroleptics: from dogma to reason. Washington DC: American Psychiatric Press, 1987:33–54.
98. Glazer WM, Hafez HM, Benarroche CL, Molindone and haloperidol in tardive dyskinesia. J Clin Psychiatry 1985;46(8, suppl):4–7.
99. Borison RL, Shah C, White TH, et al. Atypical and typical neuroleptics and tardive dyskinesia. Psychopharmacol Bull 1987;23:218–20.
100. Small JG, Milstein V, Marhenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263–7.